DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Hims & Hers Health ($HIMS): April 2026 deep dive after the GLP-1 reset, the Novo pivot, and the new peptide optionality

A full April 2026 Merlintrader-style update built on our prior HIMS work and focused on what changed since the last report: the Q4 and full-year 2025 numbers, the strategic reset in U.S. weight loss, the agreement with Novo Nordisk, the still-pending Eucalyptus acquisition, the slowing but still meaningful 2026 growth outlook, and the fresh peptide angle that has suddenly reopened part of the long-term story.

Elon Musk, Tesla, SpaceX, xAI and Grok: Building an Ecosystem for Humanity’s Future

Elon Reeve Musk, born on June 28, 1971, in Pretoria, South Africa, has become one of the most influential and polarizing entrepreneurs of the modern era. Over the past three decades, he has played a central role in reshaping digital payments, electric vehicles, reusable rockets, satellite connectivity, artificial intelligence, neural interfaces and social platforms. More than a businessman in the traditional sense, Musk positions himself as an engineer-entrepreneur obsessed with long-term civilizational questions.

$IMMP After TACTI-004: What Broke, What Survived, and Why Immutep Still Has a Real Recovery Debate

Immutep is no longer a simple high-upside oncology story. It is now a damaged but still very much alive recovery case. The flagship Phase III dream in first-line NSCLC broke hard, the stock’s credibility took a real hit, and the market had to reprice the company in a hurry. But the company did not come out of that blow as an empty shell. It still has cash, still has surviving clinical branches, still has outside validation, and now has a fresh FDA orphan drug designation in soft tissue sarcoma that puts a real regulatory spotlight back on eftilagimod alfa.

Can Cannabis Regulation in Maryland, Massachusetts, and California Become a Sector Catalyst for $ACB, $CGC, $TLRY, $CRON, and $SNDL?

Three separate state-level moves — Maryland’s public-health labeling discussion, Massachusetts’ near-term governance and licensing overhaul, and California’s pesticide testing rulemaking — may not look like classic headline catalysts at first glance. But for cannabis operators, labs, manufacturers, packaging vendors, distributors, and investors watching margin pressure, market access, and compliance risk, these are exactly the types of regulatory shifts that can quietly reshape the sector.

Robinhood Markets ($HOOD): why the new intraday-margin era matters, and why the story is bigger than the old PDT rule

Robinhood Markets, Inc. (NASDAQ: HOOD) is a commission-free, SEC-registered brokerage that has fundamentally disrupted retail investing access in the U.S. Since its 2013 founding and 2021 IPO, Robinhood has amassed ~24 million funded accounts managing $1.5+ trillion in assets. The platform generates revenue through payment for order flow (PFOF), margin lending, and cryptocurrency services—not traditional commissions.

Webull ($BULL) Deep Dive: Why the End of the Legacy Pattern Day Trader Rule Could Matter More Here Than Almost Anywhere Else

Webull is one of the most direct public-market expressions of a very specific regulatory story: the SEC has approved FINRA’s proposal to remove the old pattern day trader regime, including the long-standing $25,000 minimum equity requirement and the three-day-trade limit that restricted smaller margin accounts. That does not mean the new system is live everywhere today. It means the direction of travel is now official, the market can underwrite the path, and brokers most exposed to active retail behavior suddenly have a new narrative runway.

Safe Pro Group ( $SPAI ) Deep Dive: Why Today’s U.S. Army Exercise Matters

Today’s update did not change the fact that Safe Pro is still a very early, very promotional, very high-risk small cap. What it did change is the quality of the operating narrative. Safe Pro is no longer talking only about future opportunity in defense AI. It is now stacking a visible sequence of milestones: a government subcontract, rapid delivery, Army exercises, commercial rollout of NODE-X, and another field validation event announced today.

Amazon ($AMZN), Globalstar ($GSAT), and AST SpaceMobile ($ASTS): why Amazon’s Globalstar deal matters far beyond one takeover

Amazon’s move on Globalstar is not just another satellite headline. It is a deeper attempt to own spectrum, device-level connectivity, Apple continuity, and a bigger slice of the space economy at the same time. That has immediate implications for Globalstar, material strategic implications for Amazon, and a more complicated read-through for AST SpaceMobile.

Fastly (FSLY): verified April 2026 deep dive on the edge-security rerating thesis

Fastly is no longer the same simple “broken CDN turnaround” story it looked like a couple of years ago. The April 2026 setup is more nuanced. The business is showing real improvement in mix and operating profile, 2025 revenue accelerated to 15% growth, free cash flow turned positive, non-GAAP operating income turned positive for the full year, and management guided to another year of revenue growth plus positive non-GAAP operating income in 2026. That is the hard foundation the market was missing for a long time.

Teva Pharmaceuticals: Pivot to Growth, Now Under Real Market Scrutiny

Teva entered 2026 with a more credible transformation story than it had just a few years ago. The company reported 2025 revenue of $17.3 billion, up 4% year over year, marking its third consecutive year of growth. That matters because Teva is still carrying the legacy of a global generics business, but the mix is gradually shifting toward innovative medicines, biosimilars, and pipeline assets that management believes can support more durable long-term growth.

Travere Therapeutics ( $TVTX ) after FILSPARI’s FDA approval in FSGS

Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.

HOTH Therapeutics (NASDAQ: $HOTH): today’s HT-VA GDNF update matters, but the balance sheet still controls the story

Hoth added another mechanistic layer to its HT-VA obesity / fatty-liver narrative today, with gene-level data showing reduced Srebf1 and increased Pparα in a VA / Emory CRADA model. That strengthens the scientific story, but it does not remove the core market question: can HOTH turn early preclinical promise and encouraging HT-001 oncology-supportive data into a financed, executable development path without crushing dilution?

Momentus ( $MNTS ) Deep Dive 2026 UPDATED APRIL15

Momentus is still one of the most binary small-cap space stories on the board, but after the last two weeks it is harder to dismiss the company as a pure concept trade. The central reason is not a promotional headline. It is sequence. For a company like MNTS, sequence is everything.